Diethylamine

Summary

Diethylamine (CHEMBL1189) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including osteoarthritis, knee.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Chemistry: 73.14 Da · C4H11N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1189
Name	Diethylamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	8021
ChEBI	CHEBI:85259
Molecular formula	C4H11N
Molecular weight	73.14
InChIKey	HPNMFZURTQLUMO-UHFFFAOYSA-N

SMILES: CCNCC

IUPAC name: N-ethylethanamine

ChEBI definition: A secondary aliphatic amine where both N-substituents are ethyl.

Also known as: Diethylamine, Diethyl-amine, SID17389600, SID144209704, DIETHYLAMINE

Patent coverage: 131,756 distinct patent families (411,876 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 411,871 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Cellular tumor antigen p53.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TP53	8.1	Potency	7.9	nM	CHEMBL_ACT_4882463

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).